ACE and chronic kidney disease: ACE inhibitors or ARBs are particularly preferred in the setting of severe albuminuria (ACR > 300 mg/g), as their use has been associated with improvements in patient-important outcomes, including a reduction in CKD progression to ESRD (62–64).